Shanton Pharma

Executive Summary

Shanton Pharma is a clinical-stage biotechnology company dedicated to addressing unmet medical needs in gout, hyperuricemia, and pruritus. Founded in 2016 and headquartered in Princeton, New Jersey, the company leverages innovative small molecule approaches to develop novel therapeutics. Its focus on these underserved areas positions it to capture significant market opportunities, given the growing prevalence of gout and the lack of effective treatments for chronic pruritus. While the company is private and has not disclosed its total funding or valuation, its progression to Phase 2 clinical trials indicates meaningful preclinical and early clinical validation. Shanton's strategy of targeting multiple indications within related disease pathways may allow for efficient resource utilization and potential synergies across its pipeline. The company's ability to advance its lead candidate(s) through clinical development will be critical for attracting partnerships or financing to support later-stage trials. With a lean team focused on core therapeutic areas, Shanton Pharma represents a high-risk, high-reward opportunity in the specialty pharmaceutical space.

Upcoming Catalysts (preview)

• Q1 2026Phase 2 data readout for gout/hyperuricemia candidate40% success
• Q2 2026IND submission for pruritus program60% success
• Q3 2026Potential partnership or licensing deal for Asian markets30% success